Responses
Spondyloarthritis
Continuing versus withdrawing ixekizumab treatment in patients with axial spondyloarthritis who achieved remission: efficacy and safety results from a placebo-controlled, randomised withdrawal study (COAST-Y)
Compose a Response to This Article
Other responses
No responses have been published for this article.